Integra LifeSciences Holdings Corporation extended the termination date of its $150 million accounts receivable securitization facility to April 10, 2029, through amendments to its financing agreements.
Key takeaways
The company extended its $150 million accounts receivable securitization facility termination date to April 10, 2029.
Amendment No. 8 to the Receivables Financing Agreement implements amendments to certain customary representations and covenants.
Amendment No. 1 to the Purchase and Sale Agreement implements amendments to certain customary representations and covenants.
The amendments adjust customary concentration limits applicable to receivables in the facility.
The facility was originally established to reduce revolving borrowings and provide additional liquidity.